Summary & Overview

Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

DRG 821 encompasses lymphoma and leukemia cases with major operating room procedures and an accompanying Complication or Comorbidity, reflecting significant surgical and perioperative resource use. Correct assignment affects inpatient reimbursement because the Diagnosis-Related Group weights Medicare payments to hospitals based on clinical complexity and procedures performed.

Lymphoma and Leukemia with Major O.R. Procedures with CCDRG Lymphoma and Leukemia with Major O.R. Procedures with CCDRG 821Diagnosis-Related GroupInpatient ReimbursementMedicareHematologySurgical OncologyMajor Operating Room Procedures

DRG 821 Overview

DRG 821 covers hospital admissions for patients with lymphoma and leukemia who undergo major operating room procedures and have a Complication or Comorbidity. This group captures high-resource surgical oncology and hematologic procedures that increase inpatient costs and length of stay. It matters for Medicare payment because the Classification allocates higher reimbursement to account for operative complexity and the presence of additional clinical complications. Accurate coding of principal diagnosis, procedures, and Complication or Comorbidity is essential to assign this Diagnosis-Related Group correctly.

National Payment Rates

Across commercial payers the published rates range from about $20K (Blue Cross Blue Shield) up to $85K (Anthem), with a widest spread of $65K between the lowest and highest reported payer. The payer-level distribution in the table and the payer benchmark chart below illustrate median and interquartile variability by payer such as Aetna, Anthem, Cigna, and Blue Cross Blue Shield. Use the table and chart below for detailed percentile values and distribution shapes.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($23.5k), average submitted covered charges ($118.0k), average Medicare payment ($18.7k), and total discharges (829).

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$24K	$120K	$19K	830

Patient Population

This DRG’s population includes both Medicare-age and working-age patients, reflecting a mixed-age payer distribution rather than being confined to Medicare only. Medicare beneficiaries represent a substantial portion of inpatient utilization, but commercial payers also comprise a meaningful share of cases. Overall, the population skews toward a mixed payer mix with notable Medicare representation.

Summary & Overview

Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

DRG 821 Overview

National Payment Rates

Mean Rates by Payer — National — DRG 821

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$24K	$120K	$19K	830

Patient Population

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska shows a payer mean range from $35K to $54K across payers, with Cigna at the high end and Blue Cross Blue Shield and Anthem at the low end. The most notable deviation from national averages is Cigna’s mean of $54K, which is well above the national Cigna mean. Reference the table and chart below for payer-specific percentiles and distribution.

Key Insights for Alaska

Highest paying payer: Cigna (mean $54K); Lowest paying payers: Blue Cross Blue Shield and Anthem (both mean $35K).
Alaska’s payer means range from $35K to $54K, with Cigna notably above national Cigna mean (~$37K), indicating a meaningful upward deviation for this payer in the state.

Clinical Trials

Acute perioperative trials assessing optimized management strategies for patients with lymphoma or leukemia undergoing major operative procedures and presenting with complications (the CC component). These studies focus on interventions such as perioperative transfusion protocols, antimicrobial prophylaxis regimens, and enhanced hemodynamic monitoring in the immediate pre-, intra-, and post‑operative period for immunocompromised oncology patients. Results inform clinicians about strategies that may reduce operative morbidity, shorten ICU stays, and lower complication-related costs important for hospital reimbursement and resource allocation for this high-acuity DRG.
Comparative effectiveness studies evaluating alternative inpatient treatment pathways for complex hematologic malignancy patients who require major procedures and have comorbid complications. Examples include comparing intensive inpatient multidisciplinary care bundles (surgical, hematology/oncology, infectious disease, and transfusion coordination) versus standard care on outcomes like length of stay, readmission, and aggregate inpatient costs. These studies are relevant to providers and payers because they identify care models that may improve outcomes while optimizing utilization and DRG-based payment efficiency for a population with variable resource needs.
Post-discharge outcomes and health services research tracking recovery, readmissions, and long-term functional status after major OR procedures in lymphoma and leukemia patients with complications. Cohort studies and registry-based analyses examine predictors of 30- and 90-day readmission, durable morbidity, and downstream resource use (home health, rehabilitation, outpatient transfusions) to understand continuity of care needs. Findings help hospitals and payers plan transitional care interventions, anticipate post-acute costs, and target quality improvement to reduce preventable readmissions for this high-risk DRG.

Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

Showing 1–10 of 27

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

DRG 821 Overview

National Payment Rates

Patient Population

OpenPayer

Summary & Overview

Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

DRG 821 Overview

National Payment Rates

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes